UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
| ||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ALLAKOS INC | COM | 01671P100 | 385,073 | 86,533 | SH | SOLE | 86,533 | 0 | 0 | ||
| ALPS ETF TR | ALERIAN MLP | 00162Q452 | 1,140,175 | 29,500 | SH | SOLE | 29,500 | 0 | 0 | ||
| BRIDGETOWN HOLDINGS LTD | *W EXP 09/30/202 | G1355U121 | 6,970 | 39,773 | SH | SOLE | 39,773 | 0 | 0 | ||
| CABALETTA BIO INC | COM | 12674W109 | 335,602 | 40,581 | SH | SOLE | 40,581 | 0 | 0 | ||
| COMPASS THERAPEUTICS INC | COM | 20454B104 | 675,451 | 211,740 | SH | SOLE | 211,740 | 0 | 0 | ||
| ELEVATION ONCOLOGY INC | COM | 28623U101 | 129,815 | 68,324 | SH | SOLE | 68,324 | 0 | 0 | ||
| LANVIN GROUP HOLDINGS LIMITE | *W EXP 01/14/202 | G5380J118 | 4,500 | 12,000 | SH | SOLE | 12,000 | 0 | 0 | ||
| MOLECULAR TEMPLATES INC | COM | 608550109 | 779,931 | 2,052,991 | SH | SOLE | 2,052,991 | 0 | 0 | ||
| NEWAMSTERDAM PHARMA COMPANY | *W EXP 11/22/202 | N62509117 | 40,533 | 21,333 | SH | SOLE | 21,333 | 0 | 0 | ||
| REZOLUTE INC | COM NEW | 76200L309 | 2,694,061 | 1,403,157 | SH | SOLE | 1,403,157 | 0 | 0 | ||
| SAVARA INC | COM | 805111101 | 13,448,274 | 6,896,551 | SH | SOLE | 6,896,551 | 0 | 0 | ||
| SPDR S&P 500 ETF TR | TR UNIT | 78462F103 | 6,528,542 | 15,947 | SH | SOLE | 15,947 | 0 | 0 | ||
| SPDR SER TR | S&P OILGAS EXP | 78468R556 | 2,232,825 | 17,500 | SH | SOLE | 17,500 | 0 | 0 | ||
| VECTIVBIO HLDG AG | ORD SHS | H9060V101 | 1,345,549 | 156,651 | SH | SOLE | 156,651 | 0 | 0 | ||
| XERIS BIOPHARMA HOLDINGS INC | COM | 98422E103 | 9,843,616 | 6,039,028 | SH | SOLE | 6,039,028 | 0 | 0 | ||
